Pleuropulmonary disease associated with dopamine agonist therapy.
Artificial dopamine agonists are widely employed for the treatment of idiopathic parkinsonism. Pleuropulmonary disease has previously been reported to occur with the use of bromocriptine and mesulergine. We report similar adverse effects induced by the newer agonists lisuride and cabergoline. All these agents are tetracyclic ergot derivatives. This suggests a causal link between ergot-derived dopamine agonists and pleuropulmonary disease.
Belzberg Laboratory of Clinical Neuroscience, Vancouver, Canada.
M H
MH
Bhatt
S P
SP
Keenan
J A
JA
Fleetham
D B
DB
Calne
D000368:Aged; D000077465:Cabergoline; D015259:Dopamine Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004873:Ergolines / Q000009:adverse effects; D005260:Female; D006801:Humans; D008090:Lisuride / Q000009:adverse effects; D008171:Lung Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy; D010995:Pleural Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging; D011859:Radiography
D015259:Dopamine Agents; D004873:Ergolines; D008090:Lisuride; D000077465:Cabergoline